Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile

Somatic mutations in genes such as ASXL1, RUNX1, TP53 or EZH2 adversely affect the outcome of patients with myelodysplastic syndromes (MDS). Since selective BCL-2 inhibition is a promising treatment strategy in hematologic malignancies, we tested the therapeutic impact of ABT-199 on MDS patient samp...

Descripción completa

Detalles Bibliográficos
Autores principales: Reidel, Veronika, Kauschinger, Johanna, Hauch, Richard T., Müller-Thomas, Catharina, Nadarajah, Niroshan, Burgkart, Rainer, Schmidt, Burkhard, Hempel, Dirk, Jacob, Anne, Slotta-Huspenina, Julia, Höckendorf, Ulrike, Peschel, Christian, Kern, Wolfgang, Haferlach, Torsten, Götze, Katharina S., Jilg, Stefanie, Jost, Philipp J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper: Autophagy and Cell Death
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915115/
https://www.ncbi.nlm.nih.gov/pubmed/29707107
http://dx.doi.org/10.18632/oncotarget.24775

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915115/
https://www.ncbi.nlm.nih.gov/pubmed/29707107
http://dx.doi.org/10.18632/oncotarget.24775

Ejemplares similares